Share on StockTwits

A number of stock research firms have changed their ratings and price targets for Core Laboratories (NYSE: CLB) during the last seven days:

  • Core Laboratories had its price target lowered by analysts at Barclays from $198.00 to $181.00.
  • Core Laboratories was upgraded by analysts at Morgan Stanley from an “underweight” rating to an “equal weight” rating.
  • Core Laboratories was downgraded by analysts at Iberia Capital from an “outperform” rating to a “sector perform” rating.
  • Core Laboratories had its price target lowered by analysts at Cowen and Company from $170.00 to $160.00. They now have a “market perform” rating on the stock.
  • Core Laboratories had its price target lowered by analysts at RBC Capital from $235.00 to $180.00. They now have a “sector perform” rating on the stock.
  • Core Laboratories had its price target lowered by analysts at Howard Weil from $222.00 to $189.00. They now have a “sector outperform” rating on the stock.
  • Core Laboratories had its price target lowered by analysts at Natixis from $190.00 to $170.00.
  • Core Laboratories was upgraded by analysts at ING to a “buy” rating.

Shares of Core Laboratories (NYSE:CLB) opened at 160.96 on Wednesday. Core Laboratories has a one year low of $133.02 and a one year high of $221.00. The stock’s 50-day moving average is $191.4 and its 200-day moving average is $189.3. The company has a market cap of $7.223 billion and a P/E ratio of 29.50.

Core Laboratories N.V. (NYSE:CLB) is a provider of reservoir description, production enhancement and reservoir management services to the oil and gas industry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.